Market Closed -
Nasdaq
01:30:00 23/05/2024 am IST
|
5-day change
|
1st Jan Change
|
9.65
USD
|
+2.12%
|
|
-0.21%
|
-43.40%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,604
|
1,539
|
-
|
-
|
Enterprise Value (EV)
1 |
2,140
|
1,062
|
846.3
|
1,539
|
P/E ratio
|
-4.7
x
|
-6.51
x
|
-6.16
x
|
-5.66
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
42.5
x
|
EV / Revenue
|
-
|
-
|
-
|
42.5
x
|
EV / EBITDA
|
-8.51
x
|
-4.34
x
|
-3.12
x
|
-4.72
x
|
EV / FCF
|
-13.1
x
|
-5.02
x
|
-3.4
x
|
-5.24
x
|
FCF Yield
|
-7.64%
|
-19.9%
|
-29.4%
|
-19.1%
|
Price to Book
|
5.77
x
|
5.53
x
|
3.58
x
|
2.74
x
|
Nbr of stocks (in thousands)
|
1,52,703
|
1,59,524
|
-
|
-
|
Reference price
2 |
17.05
|
9.650
|
9.650
|
9.650
|
Announcement Date
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
36.21
|
EBITDA
1 |
-
|
-251.4
|
-244.3
|
-271.2
|
-325.8
|
EBIT
1 |
-
|
-252.1
|
-253.5
|
-286.9
|
-338.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-935.19%
|
Earnings before Tax (EBT)
1 |
-
|
-235.7
|
-244.4
|
-284.3
|
-418.9
|
Net income
1 |
-130.9
|
-235.9
|
-237.3
|
-270.8
|
-323
|
Net margin
|
-
|
-
|
-
|
-
|
-892.1%
|
EPS
2 |
-0.6100
|
-3.630
|
-1.482
|
-1.566
|
-1.706
|
Free Cash Flow
1 |
-
|
-163.4
|
-211.5
|
-249
|
-293.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-810.54%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/05/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-56.69
|
-113.8
|
-
|
-60
|
-62
|
-62
|
-
|
-
|
EBIT
1 |
-56.86
|
-114
|
-60.07
|
-62.3
|
-65.39
|
-67.94
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-53.03
|
-108.5
|
-53.72
|
-60.73
|
-63.97
|
-65.93
|
-
|
-
|
Net income
1 |
-53.03
|
-108.7
|
-53.72
|
-60.73
|
-63.97
|
-65.93
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.7100
|
-0.3400
|
-0.3745
|
-0.3942
|
-0.3922
|
-0.3800
|
-0.3900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/11/23
|
07/03/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
464
|
478
|
693
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-163
|
-212
|
-249
|
-294
|
ROE (net income / shareholders' equity)
|
-
|
-51.2%
|
-58.6%
|
-65.5%
|
-51.6%
|
ROA (Net income/ Total Assets)
|
-
|
-51.2%
|
-53.6%
|
-58.6%
|
-47.4%
|
Assets
1 |
-
|
461.2
|
442.5
|
462.4
|
680.9
|
Book Value Per Share
2 |
-
|
2.950
|
1.740
|
2.700
|
3.520
|
Cash Flow per Share
2 |
-
|
-2.510
|
-0.8900
|
-0.9500
|
-
|
Capex
1 |
-
|
0.12
|
0.1
|
0.1
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/05/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
9.65
USD Average target price
23.84
USD Spread / Average Target +147.06% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.40% | 153.94Cr | | +64.23% | 6.26TCr | | -2.31% | 4.12TCr | | +43.96% | 4.03TCr | | -8.29% | 2.79TCr | | +11.97% | 2.62TCr | | -21.16% | 1.91TCr | | +7.54% | 1.31TCr | | +27.17% | 1.21TCr | | +25.72% | 1.23TCr |
Other Biotechnology & Medical Research
|